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Abstract Peritoneal dialysis (PD) is widely employed as a
dialytic therapy for uraemic children, especially in its
automated form (APD), that is associated with less burden
of care on patient and family than continuous ambulatory
PD. Since APD offers a wide range of treatment options,
based on intermittent and continuous regimens, prescription
can be individualized according to patient’s age, body size,
residual renal function, nutritional intake, and growth-
related metabolic needs. Transport capacity of the peritoneal
membrane of each individual patient should be assessed, and
regularly monitored, by means of standardized peritoneal
function tests validated in pediatric patients. To ensure
maximum recruitment of peritoneal exchange area, fill
volume should be scaled to body surface area and adapted
to each patient, according to clinical tolerance and intraper-
itonealpressure.PDsolutionsshouldbe employed according
to their biocompatibility and potential ultrafiltration capac-
ity; new pH-neutral, glucose-free solutions can be used in an
integrated way in separate dwells, or by appropriately
mixing during the same dialytic session. Kinetic modelling
software programs may help in the tailoring of PD
prescription to individual patients’ characteristics and needs.
Owing to advances in the technology of new APD machines,
greater programming flexibility, memorized delivery con-





Chronic peritoneal dialysis (CPD) currently represents the
dialysis treatment modality most commonly prescribed for
pediatric patients with end-stage renal disease throughout
much of the world, and the preference for CPD over
haemodialysis is most pronounced among infants and
young children 0 to 5 years of age [1–3].
In this study we addressed the issues of CPD modality
selection and prescription, including some technical aspects
of the modalities; for reason of space, an effort has been
made to summarize accurately current knowledge specific to
these issues, but readers are encouraged to consult references
cited throughout thepaperformoredetailsonspecific topics.
Selection of peritoneal dialysis modality The aim of the
process of CPD modality selection and prescription is to
tailor the treatment schedule to the needs of each individual
patient, according to a series of parameters such as the
patient’s age, body size, associated non-renal diseases,
residual renal function (RRF), clinical conditions, blood
pressure, nutritional status, and transport characteristics of
the peritoneal membrane (PM). At the same time, potential
negative effects of CPD treatment on the patient’s metab-
olism and on PM viability should be taken into account.
Finally, the burden of CPD treatment should be compatible
with a satisfactory level of psychological and social
rehabilitation of the patient and of his/her family. During
the past 10–15 years, several technical improvements in
materials and devices for peritoneal dialysis (PD), the
development of more biocompatible PD solutions, and the
employment of computer technology, have provided dialy-
sis staff with valuable tools to improve the efficacy and
tolerability of CPD treatment and also to check that the
treatment dose has been delivered.
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Peritoneal membrane function tests
Peritoneal solute and fluid transport may vary considerably
from patient to patient and in the same patient during
different phases of CPD treatment, as a consequence of the
recurrence and/or severity of peritonitis episodes or of the
exposure of the PM to CPD solutions and materials.
Therefore, PM transport characteristics should be assessed
at the beginning of CPD (usually a month after the patient
has started peritoneal dialysis) and then monitored every 6–
12 months and during recurrent or particularly severe
peritonitis or any other clinical event that may cause
changes in transport capacity [4, 5].
The application of PM function tests to paediatric
patients has long been hampered by a lack of standardiza-
tion of dialysis mechanics during the test. Appropriate
scaling for body size plays a central role for this
standardization and for the calculation of membrane
function parameters. While in infants the peritoneal surface
area per unit body weight (BW) is twice that of adults, the
relationship between body surface area (BSA) and PM
surface area is constant and age independent. In early
pediatric transport studies, standardization of exchange
volumes by BW led to a false perception of differences in
peritoneal permeability between children and adults, with
an enhanced transport function in the youngest patients that
was due to faster solute equilibration associated with the
use of relatively small dwell volumes [6]. On the contrary,
scaling the exchange volume by BSA maintains the
relationship between dialysate volume and PM surface area
across populations, and makes comparison of peritoneal
transport properties between patients of different body sizes
possible [7, 8]. An exchange volume of 1,100 ml/m
2 BSA
approximates the standard BSA-based volume of 2,000 ml/
1.73 m
2 applied to adult patients.
Measurement of mass transfer area coefficient Diffusive
permeability of the peritoneal membrane can be expressed
by means of the mass transfer area coefficient (MTAC),
which describes the maximum clearance theoretically
achievable at a constantly maximum gradient for diffusion
(i.e. when dialysate solute concentration is zero) and is
independent of dialysate glucose concentration. MTAC can
be calculated with the help of computer technology, which
can give reliable results also in pediatric patients [9].
Comparison of MTAC values obtained in patients of
different ages is possible if exchange volume has been
standardized to BSA [9, 10]. However, relatively greater
solute transport capacity has been reported in infants, as a
consequence of higher peritoneal permeability or larger
effective surface area of the peritoneal membrane [10].
The peritoneal equilibration test This test remains the most
commonly employed means of characterizing PM transport
capacity in adults as well as in children [10–13]. Urea and
creatinine dialysate-to-plasma (D/P) ratios and dialysate
glucose concentration to initial dialysate glucose concen-
tration at time 0 (D/D0), calculated at 2 h and 4 h of a
standard peritoneal equilibration test (PET) conducted with
a 1,100 ml/m
2 dwell volume of a 2.5% dextrose PD
solution, can be compared to the results from a large
paediatric study in which the same PET procedure was
adopted [10]. Thus, patients will be characterized as having
high, high average, low average or low, solute transport
(Table 1). Similarly to what has been reported in adult
patients, the high transporter status may be associated with
poor treatment outcome and has been identified as a
significant risk factor for inadequate weight control, poor
statural growth [14], and low-turnover bone disease [15].
The PET can be also performed with a 4.25% dextrose
PD solution to obtain more accurate information on
ultrafiltration (UF) capacity and sodium sieving [16].
Recently, Warady and Jennings reported that the PET
results obtained at 2 h and 4 h, based on either creatinine or
glucose transport in 20 children who had been on PD for
7 months or less, provided identical characterization of
peritoneal membrane transport capacity for the same solute
[17]. Therefore, the authors proposed the use in paediatric
patients of a simplified, 2 h PET procedure, the so-called
short PET, as already described in adult patients by
Twardowski et al. in the original publication of the PET [11].
Table 1 Peritoneal equilibration test results for urea, creatinine and
glucose. The four categories of peritoneal transport are bordered by
the maximum, mean + 1 standard deviation (SD), mean, mean −1 SD,
and minimum values for the study population. D/P dialysate-to-
plasma ratio, D/D0 dialysate glucose to initial dialysate glucose










High 0.91–0.94 0.77–0.88 0.12–0.21
High average 0.82–0.90 0.64–0.76 0.22–0.32
Low average 0.74–0.81 0.51–0.63 0.33–0.42
Low 0.54–0.73 0.37−0.50 0.43–0.55
aAt a 4 h dwell of an exchange performed with 1,100 ml/m
2 BSA of a
2.5% dextrose solution
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and nursing staff and is associated with cost savings, the
adoption of this procedure may help in the evaluation of
transport characteristics of the peritoneal membrane on a
more routine basis among paediatric PD centres. However,
further study with a larger patient cohort is required to
confirm the accuracy of the short PET in the characterization
of membrane transport capacity in this setting [18].
Two other tests for peritoneal membrane function that
have given reliable results in adults as well as in paediatric
patients, but are less frequently employed than the PET in
the clinical setting, are the so-called standard permeability
analysis and the personal dialysis capacity test.
Standard permeability analysis In this test, polydisperse
dextran-70 is added to the PD solution employed in the
PET so that simultaneous measurement is obtained of
transcapillary ultrafiltration (UF), marker clearance rates,
and intraperitoneal volume (IPV). Standard permeability
analysis (SPA) conducted with a test IPV of 1,200 ml/m
2
and a 1.36% or 3.86% glucose PD solution gave compa-
rable results in adult and pediatric patients [19, 20].
Personal dialysis capacity test This test [21] is based on
the three-pore model of solute and fluid transport across the
peritoneum, which is characterized as a heteroporous three-
pore membrane with few (approximately 1–2%) water-
exclusive ultra-small pores, called aquaporins (radius 0.2–
0.4 nm), a small percentage (approximately 5%) of large
pores (radius 20–30 nm), and a majority (approximately
90–95%) of small pores (radius 4–6 nm). Small solute
transport occurs primarily by diffusion across the small
pores, while proteins and other macromolecules are driven
by convection across the large pores. Fluid transport is
determined by crystalloid and colloid osmotic pressures and
can occur across all three pathways. By personal dialysis
capacity (PDC) test the following three parameters can be
calculated: (1) the effective peritoneal surface area, or
unrestricted pore area over diffusion distance (A0/ΔX),
corresponding to the diffusion capacity for solutes; (2)
absorption, i.e. the final rate of fluid reabsorption from the
abdominal cavity, and (3) the large-pore volume flow,
which represents the rate of protein-rich fluid passing
through the large pores from the blood to the dialysate.
PDC protocol includes five exchanges to be performed in
24 h, using different dwell times and two glucose solutions
for patients on continuous ambulatory peritoneal dialysis
(CAPD); a simplified protocol for patients on APD is also
available [22]. The PDC test has been successfully
employed in children to model individual peritoneal
membrane function [22]. In one paediatric study, D/P or
D/D0 ratios derived from PET analysis were used to
estimate A0/ΔX with a specific computer program [23].
Peritoneal dialysis solutions
Several types of PD solutions have been made commer-
cially available that achieve satisfactory removal of fluid
and waste products and maintain acid–base and calcium
balance and electrolyte homoeostasis. The increasing
knowledge of the harmful effects of prolonged exposure
of the peritoneal membrane to standard PD solutions with
high glucose and lactate concentration, low pH, high
osmolarity, and high level of glucose degradation products
(GDPs) has led to the development of more biocompatible,
second-generation PD solutions. Studies done recently
support the hypothesis that peritoneal membrane hyper-
vascularization and fibrosis observed during long-term PD
are correlated to acute and chronic toxicity of conventional
PD fluids. Furthermore, progressive decline of residual
renal function, which is considered a major determinant of
PD treatment outcome, can be exacerbated by the metabolic
and cardiovascular burden related to glucose load, GDPs
accumulation, and oxidative stress [24–26].
Glucose remains the most widely employed osmotic
agent in the clinical setting. The crystalloid osmotic effect
of glucose, which is exerted through the aquaporins, can be
effectively enhanced by increasing its concentration in the
PD fluid. The rapid and variable absorption rate of glucose
from the peritoneal fluid dissipates the osmotic gradient and
makesitunsuitabletoobtainadequateUFduringlongdwells
and in patients with high peritoneal transport rates. Glucose
absorption may worsen the anorexia, hyperglycaemia,
dyslipidaemia, and insulin resistance as well as the increased
oxidative stress that are often associated with the uraemic
syndrome. Moreover, long-term exposure to the elevated
glucose concentration of PD fluids contributes to structural
(submesothelial thickening and fibrosis, and vascular prolif-
eration) and functional (UF failure) changes in the peritoneal
membrane. The main mechanisms by which glucose-based
PD fluids induce these deleterious effects on peritoneum are
represented by:
– hyperosmolar stress
– the presence of highly reactive glucose GDPs that
impair mesothelial cell function and modulate cytokine
generation
– glycation of structural proteins and formation of
advanced glycation end products (AGEs)
– effects on peritoneal cell metabolism via the polyol
pathway, protein kinase activation and gene induction
[26–28].
Reduced formation of GDPs has been obtained by the
separation of glucose from other contents in a double-
chamber bag system that allows glucose sterilization at a
lower pH than is possible in single-chamber bags [28, 29].
Significant reduction of plasma AGE levels has been
Pediatr Nephrol (2009) 24:1453–1464 1455reported in paediatric patients by administration of low-
GDP PD solutions [30].
In summary, glucose is effective in UF induction along
short dwells, but the lowest glucose concentration of PD
solution should be used in daily practice while still being
compatible with the patient’s clinical needs [31].
Icodextrin As an alternative to glucose-based PD solutions
during prolonged dwells, PD solutions containing a
polymer of glucose with an average molecular weight
(MW) of 16,200 Da (icodextrin) have been extensively
studied and applied to adult PD patients. The colloid
osmotic effect of a 7.5% icodextrin solution that is exerted
through the small pore was able to obtain sustained, net UF
during a 14 h dwell [32]. Studies in paediatric patients
showed the same UF profile as in adults, an increase in
solute removal, and rare, mild side effects (skin rash) [33–
35]. By comparing the results of two 4 h PETs, performed
on nine paediatric patients and using 3.86% glucose and
7.5% icodextrin as a test solution, Rusthoven et al. [36]
found that the two solutions had different effects on the
change in intraperitoneal pressure (IPP); during the PET
performed with a 3.86% glucose solution, the increase in
IPP was positively correlated with transcapillary UF and
inversely correlated with the patients’ BSA, while, by using
an icodextrin solution, they found that the IPP hardly
increased during the 4 h dwell and no correlation was found
with fluid kinetics or patient BSA.
Since the colloid osmotic effect exerted by icodextrin
does not induce sodium sieving, sodium removal is usually
higher than that obtained with glucose-based solutions [37].
In children icodextrin absorption was reported to be 45%
over 14 h [34]. Icodextrin is metabolized by amylase to
maltose and a number of oligosaccharides, whose serum
levels usually reach a steady state within 2 weeks from the
start of treatment and go back to zero 2 weeks after
discontinuation of the use of icodextrin solution [33]. Sterile
peritonitis was reported in some patients treated with
icodextrin and was caused by peptidoglycan contamination
of the dialysate by thermophilic, acidophilic bacteria [38].
In vitro and ex vivo studies have shown that icodextrin
solution is more biocompatible with the peritoneal mem-
brane than is glucose-based solutions, possibly due to its
iso-osmolar property, lack of glucose, and lower GDP
content [39]. However, it has been recently reported that
icodextrin may also inhibit the normal process of mesothe-
lial cell repopulation and induce repair by means of
connective tissue formation [40].
In summary, icodextrin solution is indicated for: long
night-time dwell in continuous ambulatory PD (CAPD);
long daytime dwell in continuous cycling PD (CCPD);
patients with type I UF failure or transient UF failure
associated with peritonitis. Icodextrin is currently licensed
for use in not more than one dwell per day, out of concern
for the potential side effects of its low molecular weight
metabolites.
Combination of different solutions With the aim of
optimizing fluid removal and reducing glucose exposure,
a combination solution of glucose and icodextrin has
been employed with encouraging results during a daytime
dwell in adult patients. [41, 42]. Studies on the use of
bimodal PD solutions in paediatric patients should be
encouraged.
The concept of prescribing a mixture of dialysis fluids in
order totakethemaximumadvantageofeachcomponenthas
been applied to the use of amino acid (AA) PD solutions. In
children on CAPD the effect on nutritional status of using an
AA solution in a long dwell was anecdotal. Increases in
blood urea nitrogen and worsening of acidosis have been
observed [43]. On the other hand, combined intraperitoneal
infusion of AA and glucose during nocturnal APD sessions
promoted the utilization of AA for protein synthesis [44].
This schedule was reported to improve anthropometric
parameters in children on APD [45] and to influence
positively muscle protein turnover in adult patients [46].
A 1.1% AA solution is as osmotically efficient as a 1.36%
glucose solution is; moreover, a certain increase in solute
removal and UF may be expected, since AAs tend to induce
peritoneal vasodilatation and, hence, recruitment of microvas-
cular surface area to a greater extent than glucose does [47].
In summary, the use of AA solution in children on APD
can be indicated in order to improve treatment biocompat-
ibility and to supply AA in malnourished patients. However,
in these patients enteral nutrition should be used whenever
possible to improve nutritional status [31].
Bicarbonate-based PD solutions The use of lactate-buff-
ered PD solutions with low pH is associated with a series of
well-known clinical, metabolic and biocompatibility draw-
backs (Table 2). Neutral pH (7.0–7.6) PD solutions
containing, 34 mmol/l of bicarbonate, or 25 mmol/l of
bicarbonate plus 15 mmol/l of lactate, are commercially
available in multi-compartment bag systems [31]. Adult
and paediatric studies have shown that the use of these
bicarbonate-buffered PD solutions is associated with better
biocompatibility, more effective correction of acidosis, and
lower incidence of infusion pain than that of conventional
lactate-buffered solutions [48–50]. Schmitt et al. [51] found
that peritoneal mass transfer kinetics were similar with
bicarbonate and lactate for water and most solutes, except
for slightly lower phosphate and creatinine transport rates,
at 1 h dwell time with bicarbonate solutions. These more
physiological PD fluids have been shown to prevent
hyperperfusion and to reduce the loss of proteins into
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intraperitoneal pressure, reflecting enhanced tolerance of
fill volume, but also with a reduction of the unrestricted
area over diffusion distance and of the vascular exchange
area [50].
In summary, bicarbonate seems to be the most suitable
buffer for PD solutions to be used in paediatric patients
who frequently undergo the short dwell cycles of night
APD schedules [31]. However, long term clinical trials
would be needed to confirm the impact of bicarbonate-
buffered solutions on peritoneal membrane viability.
Calcium Commercially available PD solutions contain: (1)
1.75 mmol/l of calcium; since ionized calcium in these
solutions is higher than the ionized calcium level normally
present in blood, diffusion of calcium from dialysate to
blood would lead to a positive calcium balance; (2)
1.25 mmol/l; these solutions are frequently employed with
the goal of reducing the risk of hypercalcaemia, especially
in children receiving calcium carbonate or calcium acetate
as phosphate binders and being treated with vitamin D
analogues [31]. Attention should be paid to avoid hyper-
calcaemia and a high calcium x phosphate product for the
potential risk of inducing vascular and soft tissue calcifica-
tion. Use of non-calcium-containing phosphate binders
would be indicated in these cases.
Prescription for PD regimen
PD prescription should be tailored on the basis of the
child’s age, body size, residual renal function (RRF),
nutritional intake, and transport capacity of the peritoneal
membrane. Moreover, the prescribed PD schedule should
be compatible with the psychological and social needs of
the patient and family. Technical parameters that should be
primarily considered in the prescriptive process are [4, 13,
52]:
(1) status of peritoneal membrane transport, evaluated by
means of validated functional tests
(2) PD solution, selected according to biocompatibility
and potential UF capacity
(3) fill volume, tailored to the patient’sn e e d sa n d
tolerance
(4) exchange dwell time, optimized for small and middle-
sized molecule removal and UF
Prescription of fill volume Scaling IPV by patient BSA has
become a standard in paediatric PD prescription [4, 13, 52].
IPV and the patient’s posture dynamically affect the
recruitment of an effective peritoneal membrane area for
dialytic exchange, which corresponds to the unrestricted
pore area over diffusion distance (A0/ΔX) as determined
with the three-pore model [21, 23]. Raising IPV from
800 ml/m
2 BSA to 1,400 ml/m
2 BSA leads to maximization
of peritoneal vascular surface area [23]. On the other hand,
excessive IPV may cause patients discomfort, pain,
dyspnoea, hydrothorax, hernia, gastroesophageal reflux,
and loss of UF due to increased lymphatic drainage.
Hydrostatic intraperitoneal pressure (IPP) is a reproducible
patient-characteristic parameter, and its measurement helps
to evaluate fill volume tolerance in the individual patient
[53]. For a patient in a supine position, fill volume leading
to an IPP of 18 cm H2O is considered to be the maximum
tolerable IPV, above which abdominal pain and a decrease
in respiratory vital capacity may occur [52]. An IPV of
1,400 ml/m
2 BSA seems to be the optimum for ensuring
optimal recruitment of vascular pore area in children;
however, this should be considered as a maximum limit,
the safety of which has not been validated in children. In
clinical practice, fill volume can be increased in steps up to
the limit of 1,400 ml/m
2 BSA for a night exchange, while
the patient is lying down, according to clinical tolerance
and IPP measurement [52].
Prescription of dwell time Dwell duration should always be
determined according to the individual patient’st r a n s p o r t
status [4, 13, 52]. Short exchanges lead to satisfactory
clearance of small solutes (such as urea) and UF, which can
be further enhanced by increasing dialysate glucose concen-
tration. Patients with high rates of transport would benefit
from short exchanges, due to dissipation of osmotic gradients
by fast glucose absorption. Long exchanges favour the
removal of solutes of relatively high molecular weights, such
as creatinine and phosphate, but can be associated with
Table 2 Effects of toxins on membrane integrity (left side of table)
and clinical and metabolic drawbacks (right side of table) that may be
correlated with the use of lactate-buffered PD solutions




Local release of cytokines
and growth factors:
Need of lactate conversion
to bicarbonate in the liver
→ inflammatory state
→ fibrogenic processes
→ neo-angiogenesis Loss of bicarbonate due to its
back-diffusion into the dialysate → peritoneal fibrosis
Impairment of
→ mesothelial cell integrity Abdominal pain during the
inflow of dialysate → peritoneal macrophage
function
→ intraperitoneal host defence
→ membrane permeability
Pediatr Nephrol (2009) 24:1453–1464 1457impaired UF or even with dialysate reabsorption if glucose-
based solutions are being used. An icodextrin-based solution
is more appropriate for such long dwells [31, 33].
A potentially useful way to individualize dwell duration
in paediatric patients on automated PD (APD) according to
peritoneal transport capacity is the calculation of the so-
called APEX time. In the PET, the APEX time corresponds
to the point at which the D/P urea and D/D0 glucose
equilibration curves cross, and should represent the optimal
length of APD cycles [54].
The above-mentioned prescription principles should be
applied to the delivery of different PD regimens, which will
be briefly described [4, 31, 55].
Continuous ambulatory peritoneal dialysis CPD was orig-
inally performed as CAPD, a continuous regimen that
allows complete equilibration of small solutes and a certain
removal of middle-sized molecules. This PD modality has
the undoubted advantage of ease of use and limited cost of
the equipment. CAPD is usually effective in children with
RRF, but its decline should be closely monitored. Accord-
ing to the guidelines of the European Committee on
adequacy of the pediatric PD prescription [4], initial fill
volume can be 600–800 ml/m
2 during the day and 800–
1,000 ml/m
2 overnight, and can then gradually be increased
according to the patient’s tolerance and IPP measurements.
An icodextrin-based solution can be used for the prolonged
night-time dwell. As a further step, the number of
exchanges can be increased from four to five per day.
However, if increasing the number of exchanges to obtain
adequate UF and solute removal represents an excessive
burden upon the families, a shift of the patient to an APD
modality should be considered.
Automated peritoneal dialysis APD represents the PD
modality of choice for paediatric patients, at least in
countries that have no cost constraints [2, 3]. Financial
and technical problems still represent a limitation to the use
of APD for many units in developing countries.
Reasons for the preference of APD are reported in
Table 3. APD offers a wide selection of treatment schedules
that has in common the use of automated machines for fluid
delivery, currently called ‘cyclers’, and the high efficiency
obtained through short dwell times, high dialysate flows,
and large IPV.
Nightly intermittent PD Nightly intermittent peritoneal
dialysis (NIPD) consists of a number of short nocturnal
cycles, without a daytime dialysate dwell, and is primarily
indicated for patients characterized by a high-transport
peritoneal membrane, which allows rapid solute equilibra-
tion. The main advantages of a dry abdomen during the day
include normal IPP, and the reduction of glucose absorp-
tion, of AA and protein loss, and of membrane exposure to
glucose. On the other hand, the absence of a daytime dwell
is a limitation for solute clearance (especially for middle-
sized molecules), and it makes NIPD not suitable for
patients with low and low-average peritoneal transport.
NIPD is frequently adopted as the first APD regimen for
patients with a significant RRF. Then, NIPD prescription
can evolve according to clearance and UF requirements,
that are mostly dictated by the decline of RRF. NIPD
efficiency can be enhanced by increasing dwell volume,
total treatment time, and the number of exchanges up to a
point beyond which solute clearance and water removal
may decrease as the non-dialytic time, corresponding to the
fill and drain phases, becomes unacceptably long.
Tidal PD With this modality, an initial infusion of solution
into the peritoneal cavity is followed by only partial
dialysate drainage; thus, an intra-abdominal volume is
always left. Drained tidal volume is replaced with fresh
dialysis fluid to restore initial IPV, while the entire dialysate
volume is drained at the end of the PD session. The amount
of ultrafiltrate expected to be generated during each cycle
must be estimated and added to the drain volume, to
prevent overfilling of the peritoneal cavity. Continuous
contact between dialysate and peritoneal membrane
maintains a sustained diffusion of solutes, and the
efficiency of the dialysis modality is further increased
by reducing inflow and outflow dead times, particularly
when high dialysate flow rates are used. Tidal PD is
also adopted to avoid repeated cycler alarms of low
flow rate in case of catheter malfunction, and to reduce
Table 3 Reasons for preference of automated peritoneal dialysis
(APD) in paediatric patients (IPP intraperitoneal pressure, PM
peritoneal membrane)
Why APD is preferred
Wide range of treatment options




- growth-related metabolic needs
- residual renal function
- PM transport status
Large fill volume in the night-time exchanges
➔ recruitment of functional peritoneal surface area
Option of an empty abdomen during the day
- normal IPP (less risk of hernias)
- reduced glucose absorption
- reduced exposure of PM to dialysis fluid
- reduced loss of proteins and amino acids
Psychological and social rehabilitation
➔ reduced impact of treatment on patient/family lifestyle
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of tidal peritoneal dialysis (TPD) is mainly conditioned by
total volume of PD fluid delivered and by the individual’s
peritoneal transport rate. Patients with high transport rates
can reach adequate solute clearances with intermittent
nightly TPD, while patients with high average transport
rates would benefit from one or more daytime dwells [56,
57]. A further increase of TPD efficiency can be attained by
adapting tidal volume to the drainage profile of each patient,
thus reducing the fill and drain dead times [58]. In fact, the
drainage profile of peritoneal fluid is not linear, since a high
flow rate is maintained until the so-called breakpoint, when a
critical intraperitoneal volume is reached. Then, the flow rate
drops, and, during the final, slow-flow portion of the drainage
phase, the peritoneal cavity is almost empty and solute
clearance is greatly reduced [59]. Since critical intraperitoneal
volume is an individual characteristic, tidal volume can be
tailored to the drainage profile of each patient, thus reducing
idle time and improving the overall efficiency of the system.
Continuous cycling PD In CCPD, a fresh exchange of
dialysis solution, ranging in volume from 50% to 100%
of the fill volume, applied at night, is left in the
abdomen at the end of the nocturnal APD session.
Daytime exchange dialysate can be drained at bedtime,
when the cycler is reconnected, so that the patient’s
involvement is reduced to one session for preparation of
the equipment and connection to cycler, and one short
disconnection in the morning. Over a long daytime
exchange, complete equilibration of small-solute concen-
tration between plasma and dialysate is often achieved;
moreover, middle-sized uraemia toxins are poorly influ-
enced by short cycles of APD and much more dependent
on complete saturation of dialysis solution during long
dwell exchanges [60]. Phosphate PD clearance is usually
insufficient to obtain a satisfactory control of hyperphos-
phataemia, and there is a continued need for dietary
restriction and phosphate binder administration; however,
phosphate removal by PD can be improved by increasing
dwell volume and by optimizing exchange duration through
the calculation of the so-called phosphate purification dwell
time (PPT) from a PET [54].
A continuous PD regimen is recommended when RRF
becomes negligible, and it is indicated in patients with high-
average rates of peritoneal transport. Icodextrin solution is
typically employed for the long daytime exchange [31, 33, 34].
If a further increase in solute clearance and UF is desired,
more than one diurnal exchange can be performed, optimizing
the length of each dwell according to the patient’s peritoneal
transport rate and the type of osmotic agent employed
(continuous optimal peritoneal dialysis, COPD) [4, 60].
The delivered dialysis dose should be adjusted and
monitored in accordance with the 2006 update of the
National Kidney Foundation/Kidney Disease Outcomes
Quality Initiative (NKF-KDOQI) clinical practice recom-
mendations for paediatric peritoneal dialysis adequacy
(Table 4)[ 13]. In the absence of definitive results from
large randomized controlled studies on the correlation
between solute removal and clinical outcome in paediatric
patients treated by PD, current clinical opinion supports the
recommendation that the target delivered solute clearance
should meet or exceed that of the adult standards. In
patients with RRF, the contribution of renal and peritoneal
clearance can be added for practical reasons. In general,
results of the prescribed PD schedule should regularly
assessed, taking into account not only numerical targets of
small-solute depuration, but also all the parameters
involved in the definition of adequacy of dialysis treatment
in childhood, such as adequate growth, blood pressure
control, and nutritional status; avoidance of hypovolaemia
and sodium depletion; adequate psychomotor development
[4, 13, 14].
The use of software programs for APD prescription In the
clinical setting, the selection of a personalized PD schedule,
among the wide range of treatment options that are
available with APD, can be facilitated by kinetic modelling.
Mathematical modelling software programs, that have a
specific individual peritoneal function test as data entry, have
been developed to calculate kinetic parameters, to simulate
the results of APD regimens, and rapidly find the best
personalizeddialysisschedule,thusomittingthe conventional
‘trial and error’ approach [61]. Two of these software
programs have been validated in children [9, 22, 62]. The
accuracy of these mathematical models in predicting solute
removal was good, while UF prediction was less accurate.
The limited performance with respect to UF prediction
may be related to the inability of kinetic modelling to
account for changes in residual dialysate volumes, the
marked day-to-day variability of UF, the large variability
of daily fluid intake, and the confounding effect of
residual diuresis in non-anuric patients [63, 64]. Moreover,
mathematical modelling refers to perfect and virtually
uneventful APD sessions, with no alarms and no delay in
the fill and drain phases; therefore, simulation may, at times,
be ‘optimistic’. In conclusion, computer-assisted kinetic
models are useful tools for selecting the optimal dose of
dialysis for a given patient, but direct measurement of actual
solute clearances and UF rate remains mandatory.
Technical issues
Over the past 15 years, CPD has experienced a great and
quite fast evolution, which has been mostly linked to the
Pediatr Nephrol (2009) 24:1453–1464 1459development of safe and simple-to-use connecting devices,
more biocompatible solutions, and new automatic machines
for PD delivery (cyclers).
The use of an integrated Y set, double-bag system, with a
disinfectant-containingcap,anda ‘flushbeforefill’ mode,has
beenassociatedwitha reduction inthe incidence ofperitonitis
episodes due to manual contamination and has contributed to
the simplification of PD connecting manoeuvres, thus
shortening patient and partner training [55, 65–67].
Modern cyclers for APD are characterized by small size,
light weight, and portability, as well as their user-friendly
interface, which represent basic requirements for home-
based therapy devices [55, 68]. From a technical point, these
machines have a great programming flexibility and are
equipped with a cassette specific for the tubing set, and
automated devices for its connection with the dialysate bags to
minimize the risk of operator error and contamination; online
warming of dialysate; gravity-assisted pumps for dialysate
infusion and drainage; pressure monitors to assess IPP [68].
APD of paediatric patients is performed through a
specific paediatric mode of the cycler, which allows
accurate delivery of small dialysate volumes (60 ml per
exchange, with 10 ml increments), with as limited a
recirculation as possible, and drainage of peritoneal effluent
at a low flow rate without triggering the alarm.
The technology incorporated in the cyclers has also led
to the possibility of treatment prescription and events being
memorized on an electronic device, thus providing infor-
mation on the delivered dialysis dose and UF, on patient’s
compliance to APD prescription, and on peritoneal catheter
function. For instance, cyclers can record the drainage
profile of each exchange, giving graphs of the pattern of
catheter flow, and can detect the breakpoint in each cycle,
and accordingly adapt the drain profile. This database of
therapy information can be downloaded from the memory
card of the cycler during the patient’s visits to the dialysis
unit, or it can be retrieved via a modem on a regular basis.
The telecommunication link between the patient’s cycler at
home and a computer at the dialysis unit can improve the
care of patients living at distance from the dialysis centre,
through the early detection of a series of clinical and
technical problems [69]. For instance, these might be
represented by an imperceptible, but progressive, decrease
in UF rate, or by a prolongation of the drainage phase due
to a catheter malfunction that is still too small to trigger
cycler alarms. Moreover, the awareness of routine data
recording and transmission can help the patient to be more
confident of treatment control and help the dialysis doctors
and nurses to update PD prescription more rapidly. The
tele-dialysis system can also be integrated into video-
conferencing equipment to conduct tele-consultations [70,
71]. In the only available paediatric report on this kind of
tele-care support, the videophone equipment employed still
showed technical limitations and was considered to be not
cost-effective [72]; therefore, this technology deserves
further evaluation in paediatric home PD.
Further advances in cycler technology will include the
ability to optimise PD regimens, by using the recorded
information on the patient’s response to a given treatment to
suggest an improved schedule, or even to attempt to
improve it automatically. As examples, online detection of
UF could serve as information for automatic feed-back on
the bedside production of the next cycle PD fluid, which
will be individualized with respect to osmotic agent, buffer,
calcium, and sodium content [68, 73, 74].
Conclusions
In conclusion, issues that may have a major impact on the
ability to individualize PD treatment and to preserve the
efficacy of the prescribed regimen over time will be briefly
recalled (Fig. 1).
An important step in the process of individualizing PD
prescription is represented by the characterization of PM
Table 4 Solute clearance targets and measurements in children on maintenance peritoneal
Targets and measurements
The minimal delivered dose of total (peritoneal and kidney) small-solute clearance should be a Kt/Vurea of at least 1.8/week
Total solute clearance should be measured in a clinically stable patient:
➔ within the first month after dialysis has been initiated
➔ at least once every 6 months thereafter (but in patients with residual renal function 24 h urine collection for determination of volume and
solute clearance should be obtained at a minimum of every 3 months)
➔ more frequently when clinical events are likely to have resulted in decreased clearance or when new/worsening signs or symptoms of uraemia
develop
➔ at least 1 month after resolution of an episode of peritonitis
➔ if a patient is not doing well and has no other identifiable cause other than kidney failure
When calculating Kt/Vurea, V, or total body water, should be estimated by using gender-specific nomograms based upon equations that include the
patient’s height and weight [77]
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well standardized functional tests that have been validated
in paediatric patients.
Fill volume should be scaled to body surface area and
adapted to each patient, according to clinical tolerance and
IPP measurement, in order to ensure maximum recruitment
of peritoneal exchange area.
Children represent a patient category that would greatly
benefit from the use of new, more physiological and
biocompatible, PD solutions, especially if one considers
their long-term dependence on a functioning peritoneal
membrane in case of a kidney transplant failure and the fact
that, in APD, frequent short cycles continuously expose the
peritoneal membrane to a non physiological and bio-
incompatible milieu. Combined use of glucose, amino acids,
and icodextrin as part of a glucose-sparing APD regimen,
together with the adoption of pH-neutral solutions, may
represent a strategy that would adequately manage solute
removal and UF, while preserving PM integrity over time.
Fluid balance is increasingly recognized as a crucial
aspect of the PD patient’s treatment, as the efficiency of
water and salt removal is associated with patient outcome,
especially in anuric patients, and UF failure is an important
cause of failure of the technique [75].
Prospective randomized trials of dialysis adequacy and
observational studies in adult patients have confirmed that
RRF is a much stronger predictor of patient survival than
peritoneal clearance. Therefore, the PD prescription should
be aimed to preserve RRF for as long as possible [13, 76],
by gradually increasing the dialysis dose in steps, accurate-
ly targeting UF rate to maintain the patient’s dry body
weight, and using the lowest possible dialysate glucose
concentration required to achieve the desired UF volume.
Prevention of RRF loss also involves the avoidance of
nephrotoxic insults (medications, radiocontrast agents,
urinary obstruction and infection) and the use of loop
diuretics. The potential role of angiotensin-converting
enzyme inhibitors and angiotensin-receptor blockers is
worth investigating in interventional outcome studies in
children on PD. As RRF declines over time, PD prescrip-
tion should be adjusted in a timely fashion.
The evolution of APD has been closely linked with the
advances in the technology incorporated in the new cyclers
that have made APD delivery safer and more efficient.
Whether tele-dialysis is able to reduce significantly the
need for patient hospitalization or the incidence of
technique failure in a population of home APD children
should be evaluated in large-scale studies.
The ultimate goal of the whole process of PD modality
selection and prescription is to identify, and possibly
achieve, the optimal PD dose for each individual patient;
this can be regarded as the amount of dialysis above which
the additional expected benefit does not justify the increase
of the burden on patient and family and of financial costs.
Questions
(Answers appear following the reference list.)
1. On what anthropometric parameter should fill
volume prescription be scaled in paediatric patients ?
a. Weight
b. Height
c. Body surface area
d. Body mass index












4. Which of the following solutes is more efficiently










(CAPD, CCPD, NIPD, tidal) 
→ solution(s) 
→ dwell volume 
→ dwell time 














quality of life 
Fig. 1 Factors that should be accurately evaluated for each individual
patient in the process of peritoneal dialysis (PD) prescription, and PD
regimen parameters that have to be defined to achieve the final
treatment schedule (PRD primary renal disease, RRF residual renal
function)
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d. Urea
5. In what prescription parameter do nightly intermittent
PD and continuous cycling PD mainly differ from one
another?
a. Number of night-time exchanges
b. Dry or wet abdomen during the day
c. Tonicity of dialysate
d. Night-time fill volume
References
1. Hattori S, Yosioka K, Honda M, Ito H (2002) The 1998 report of
the Japanese National Registry data on pediatric end-stage renal
disease patients. Pediatr Nephrol 17:456–461
2. Verrina E, Edefonti A, Gianoglio B, Rinaldi S, Sorino P,
Zacchello G, Lavoratti G, Maringhini S, Pecoraro C, Calevo
MG, Turrini Dertenois L, Perfumo F (2004) A multicenter
experience on patient and technique survival in children on
chronic dialysis. Pediatr Nephrol 19:82–90
3. Fadrowki JJ, Frankenfield D, Amaral S, Brady T, Gorman GH,
Warady B, Furth SL, Fivush B, Neu AM (2007) Children on long-
term dialysis in the United States: findings from the 2005 ESRD
Clinical Performance Measures Project. Am J Kidney Dis 50:958–
966
4. Fischbach M, Stefanidis CJ, Watson AR (2002) Guidelines by an
ad hoc European committee on adequacy of the pediatric
peritoneal dialysis prescription. Nephrol Dial Transplant 17:380–
385
5. Morgestern B (2004) Peritoneal dialysis and prescription moni-
toring. In: Warady BA, Schaefer FS, Fine RN, Alexander SR (eds)
Pediatric dialysis. Kluwer Academic Publishers, Dordrecht, p 147
−161
6. Geary DF, Harvey EA, MacMillan JH, Goodman Y, Scott M,
Balfe JW (1992) The peritoneal equilibration test in children.
Kidney Int 42:102−105
7. Kohaut EC, Waldo FB, Benfield MR (1994) The effect of changes
in dialysate volume on glucose and urea equilibration. Perit Dial
Int 14:236−239
8. Warady BA, Alexander SR, Hossli S, Vonesh E, Geary D, Kohaut
EC (1995) The relationship between intraperitoneal volume and
solute transport in pediatric patients. J Am Soc Nephrol 5:
1935−1939
9. Verrina E, Amici G, Perfumo F, Trivelli A, Canepa A, Gusmano R
(1998) The use of the PD Adequest mathematical model in
pediatric patients on chronic peritoneal dialysis. Perit Dial Int
18:322−328
10. Warady BA, Alexander SR, Hossli S, Vonesh E, Geary D,
Watkins S, Salusky IB, Kohaut EC (1996) Peritoneal membrane
transport function in children receiving long-term dialysis. J Am
Soc Nephrol 7:2385–2391
11. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP,
Moore HL (1987) Peritoneal equilibration test. Perit Dial Bull
7:138–147
12. Schaefer F, Langebeck D, Heckert KH, Scharer K, Mehls O
(1992) Evaluation of peritoneal solute transfer by the peritoneal
equilibration test in children. Adv Perit Dial 8:410–415
13. National Kidney Foundation (2006) KDOQI clinical practice
recommendations for 2006 updates: hemodialysis adequacy,
peritoneal dialysis adequacy and vascular access. Am J Kidney
Dis 48 [Suppl 1]:S1–S322
14. Schaefer F, Klaus G, Mehls O, Mid-European Pediatric Peritoneal
Dialysis Study Group (1999) Peritoneal transport properties and
dialysis dose affect growth and nutritional status in children on
chronic peritoneal dialysis. J Am Soc Nephrol 10:1786–1792
15. Zialkowska H, Paczyk-Tomaszweska M, Debiaski A, Sawicki A,
Roszkowska-Blaim M (2003) Bone metabolism and peritoneal
membrane transport in children on chronic peritoneal dialysis.
Perit Dial Int 23:487–492
16. Pride ET, Gustafson J, Graham A, Spoinhour L, Mauck V, Brown
P, Burkart JM (2002) Comparison of a 2.5% and a 4.25% dextrose
peritoneal equilibration test. Perit Dial Int 22:365–370
17. Warady BA, Jennings J (2007) The short PET in pediatrics. Perit
Dial Int 27:441–445
18. Schaefer F (2007) The PET-iatrics of peritoneal solute transport: is
short also good for the young ones? Perit Dial Int 27:413–414
19. Reddingius RE, Schröder CH, Willems JL, Lelivelt M, Kohler
BEM, Krediet RT, Monnens LAH (1995) Measurement of
peritoneal fluid handling in children on continuous ambulatory
peritoneal dialysis using dextran 70. Nephrol Dial Transplant
10:866–870
20. Bouts AHM, Davin JC, Groothoff JW, Ploos van Amstel S,
Zweers MM, Krediet RT (2000) Standard peritoneal permeability
analysis in children. J Am Soc Nephrol 11:943–950
21. Haraldsson B (1995) Assessing the individual peritoneal dialysis
capacities of individual patients. A clinical tool based on the three-
pore model. Kidney Int 47:1187–1198
22. Schaefer F, Haraldsson B, Haas S, Simkova E, Feber J, Mehls O
(1998) Estimation of peritoneal mass transport by three-pore
model in children. Kidney Int 54:1372–1379
23. Fischbach M, Haraldsson B (2001) Dynamic changes of total pore
area available for peritoneal exchange in children. J Am Soc
Nephrol 12:1524–1529
24. Krediet RT, Lindholm B, Rippe B (2000) Pathophysiology of
peritoneal membrane failure. Perit Dial Int 20 [Suppl 4]:S22–
S42
25. Williams JD, Craig KJ, Topley N, Williams GT (2003) Peritoneal
dialysis: changes to the structure of the peritoneal membrane and
potential for biocompatible solutions. Kidney Int 63 [Suppl 84]:
S158–S161
26. Witoski J, Jorres A, Korybalska K, Ksiazek K, Wisniewska-Elnur
J, Bender TO, Passlick-Deetjen J, Breborowicz A (2003) Glucose
degradation products in peritoneal dialysis fluids: do they harm?
Kidney Int 63 [Suppl 84]:S148–S151
27. Holmes CJ, Shockley TR (2000) Strategies to reduce glucose
exposure in peritoneal dialysis. Perit Dial Int 20:S37–S41
28. Sitter T, Sauter M (2005) Impact of glucose in peritoneal dialysis:
saint or sinner. Perit Dial Int 25:415–425
29. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder
M, Lage C, Passlick-Deetjen J (2004) The Euro-Balance Trial: the
effect of a new biocompatible peritoneal dialysis fluid (Balance)
on the peritoneal membrane. Kidney Int 66:408–418
30. Schmitt CP, von Heyl D, Rieger S, Arbeiter K, Bonzel KE,
Fischbach M, Misselwitz J, Pieper AK, Schaefer F (2007)
Reduced systemic advanced glycation end products in children
receiving peritoneal dialysis with low glucose degradation product
content. Nephrol Dial Transplant 22:2038–2044
31. Schröder CH (2001) The choice of dialysis solutions in pediatric
chronic peritoneal dialysis: guidelines by an ad hoc European
Committee. Perit Dial Int 21:568–574
32. Posthuma N, ter Wee PM, Donker AJM, Oe PL, Peers EM,
Verbrugh HA (2000) Assessment of the effectiveness, safety, and
biocompatibility of icodextrin in automated peritoneal dialysis.
Perit Dial Int 20 [Suppl 2]:S106–S113
1462 Pediatr Nephrol (2009) 24:1453–146433. De Boer AW, Schröder CH, Van Vliet R, Willems JL, Monnens
LAH (2000) Clinical experience with icodextrin in children:
ultrafiltration profiles and metabolism. Pediatr Nephrol 15:21–24
34. Verrina E, Amici G, Perfumo F, Trivelli A (2001) Evaluation of
icodextrin absorption and ultrafiltration (UF) curve over a long
day dwell in children on continuous cycling peritoneal dialysis.
Perit Dial Int 21 [Suppl 1]:S93
35. van Hoeck KJ, Rusthoven E, Vermeylen L, Vandesompel A,
Marescau B, Lilien M, Schroder CH (2003) Nutritional effects of
increasing dialysis dose by adding an icodextrin daytime dwell to
nocturnal intermittent peritoneal dialysis (NIPD) in children.
Nephrol Dial Transplant 18:1383–1387
36. Rusthoven E, van der Vlugt ME, van Lingen-van Bueren LJ, van
Schaijk TCJG, Willems HL, Monnens LAH, Schroeder CH
(2005) Evaluation of intraperitoneal pressure and the effect of
different osmotic agents on intraperitoneal pressure in children.
Perit Dial Int 25:352–356
37. Rusthoven E, Krediet RT, Willems HL, Monnens LA, Schröder
CH (2005) Sodium sieving in children. Perit Dial Int 25 [Suppl 3]:
S141–S142
38. Martis L, Patel M, Giertych J, Mongoven J, Taminne M, Perrier
MA, Mendoza O, Goud N, Costigan A, Denjoy N, Verger C,
Owen WF Jr (2005) Aseptic peritonitis due to peptidoglycan
contamination of pharmacopoeia standard dialysis solution.
Lancet 365:588–594
39. Cooker LA, Holmes CJ, Hoff CM (2002) Biocompatibility of
icodextrin. Kidney Int 62 [Suppl 81]:S34–S45
40. Gotloib L, Wajsbrot V, Shostak A (2005) Osmotic agents hamper
mesothelial repopulation as seen in the doughnut in vivo model.
Perit Dial Int 25 [Suppl 3]:S26–S30
41. Freida P, Galach M, Divino Filho JC, Werynski A, Lindholm B
(2007) Combination of crystalloid (glucose) and colloid (icodex-
trin) osmotic agents markedly enhances peritoneal fluid and solute
transport during the long PD dwell. Perit Dial Int 27:267–276
42. Jenkins SB, Wilkie ME (2003) An exploratory study of a novel
peritoneal combination dialysate (1.36% glucose/7.5% icodex-
trin), demonstrating improved ultrafiltration compared to either
component studied alone. Perit Dial Int 23:475–480
43. Canepa A, Perfumo F, Carrea A, Giallongo F, Verrina E,
Cantalupi A, Gusmano R (1991) Long-term effect of amino-acid
dialysis solution in children on continuous ambulatory peritoneal
dialysis. Pediatr Nephrol 5:215–219
44. Canepa A, Carrea A, Menoni S, Verrina E, Trivelli A, Gusmano
R, Perfumo F (2001) Acute effects of simultaneous intraperitoneal
infusion of glucose and amino acids. Kidney Int 59:1967–1973
45. Canepa A, Verrina E, Perfumo F, Carrea A, Menoni S, Delucchi P,
Gusmano R (1999) Value of intraperitoneal amino acids in
children treated with chronic peritoneal dialysis. Perit Dial Int
19 [Suppl 2]:S435–S440
46. Garibotto G, Sofia A, Canepa A, Saffioti S, Sacco P, Sala MR,
Dertenois L, Pastorino N, Deferrari G, Russo R (2001) Acute
effects of peritoneal dialysis with dialysate containing dextrose or
dextrose and amino acids on muscle protein turnover in patients
on chronic renal failure. J Am Soc Nephrol 12:557–567
47. Olszowska A, Wanieski J, Werynski A, Anderstam B, Lindholm
B, Wankowicz Z (2007) Peritoneal transport in peritoneal dialysis
patients using glucose-based and amino acid-based solutions. Perit
Dial Int 27:544–553
48. Witowski J, Jorres A (2005) Effects of peritoneal dialysis
solutions on the peritoneal membrane: clinical consequences.
Perit Dial Int 25 [Suppl 3]:S31–S33
49. Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John
U, Pieper AK, Schaub TP, Passlick-Deetjen J, Mehls O, Schaefer
F (2003) Improved acidosis correction and recovery of mesothe-
lial cells mass with neutral-pH bicarbonate dialysis solution
among children undergoing automated peritoneal dialysis. J Am
Soc Nephrol 14:2632–2638
50. Fischbach M, Terzic J, Chauvé S, Laugel V, Muller A, Haraldsson
B (2004) Effect of peritoneal dialysis fluid composition on
peritoneal area available for exchange in children. Nephrol Dial
Transplant 19:925–932
51. Schmitt CP, Haraldsson B, Doetschmann R, Zimmering M,
Greiner C, Böswald M, Klaus G, Passlick-Deetjen J, Schaefer F
(2002) Effects of pH-neutral, bicarbonate-buffered dialysis fluid
on peritoneal transport in children. Kidney Int 61:1527–1536
52. Fischbach M, Dheu C, Seuge-Dargnies L, Delobbe JF (2007)
Adequacy of peritoneal dialysis in children: consider the mem-
brane for optimal prescription. Perit Dial Int 27 [Suppl 2]:S167–
S170
53. Fischbach M, Terzic J, Laugel V, Escande B, Dangelser C,
Helmstetter A (2003) Measurement of hydrostatic intraperitoneal
pressure: a useful tool for the improvement of dialysis dose
prescription. Pediatr Nephrol 18:967–980
54. Fischbach M, Lahlou A, Eyer D, Desprez P, Geisert J (1996)
Determination of individual ultrafiltration time (APEX) and
purification phosphate time by peritoneal equilibration test:
application to individual peritoneal dialysis modality prescription
in children. Perit Dial Int 16 [Suppl 1]:S557–S560
55. Verrina E, Perfumo F (2004) Technical aspects of the peritoneal
dialysis procedure. In: Warady BA, Schaefer FS, Fine RN,
Alexander SR (eds) Pediatric dialysis. Kluwer Academic Publish-
ers, Dordrecht, pp 113–134
56. Edefonti A, Consalvo G, Picca M, Giani M, Damiani B, Ghio L,
Galato R (1995) Dialysis delivery in children in nightly intermittent
and tidal peritoneal dialysis. Pediatr Nephrol 9:329–332
57. Hölltä T, Rönnholm K, Holmerg C (2000) Adequacy of dialysis
with tidal and continuous cycling peritoneal dialysis in children.
Nephrol Dial Transplant 15:1438–1442
58. Amici G (1999) Continuous tidal peritoneal dialysis. Prescription
and power. In: Ronco C, Amici G, Feriani M, Virga G (eds)
Automated peritoneal dialysis. Karger, Basel, pp 134–141
59. Brandes JC, Packard WJ, Watters SK, Fritsche C (1998)
Optimization of dialysate flow and mass transfer during automat-
ed peritoneal dialysis. Am J Kidney Dis 25:603–610
60. Freida P, Issad B (1999) Continuous cyclic peritoneal dialysis
prescription and power. In: Ronco C, Amici G, Feriani M, Virga G
(eds) Automated peritoneal dialysis. Karger, Basel, pp 99–108
61. Vonesh EF (1999) Membrane transport models and computerized
kinetic modeling applied to automated peritoneal dialysis. In:
Ronco C, Amici G, Feriani M, Virga G (eds) Automated
peritoneal dialysis. Karger, Basel, pp 15–34
62. Warady BA, Watkins SL, Fivush BA, Andreoli SP, Salusky I,
Kohaut EC, Vonesh EF (2001) Validation of PD Adequest 2.0 for
pediatric dialysis patients. Pediatr Nephrol 16:205–211
63. Ho-dac-Pannekeet MM, Atasever B, Strujik DG, Krediet RT
(1997) Analysis of ultrafiltration failure in peritoneal dialysis
patients by means of standard peritoneal permeability analysis.
Perit Dial Int 17:144–150
64. Mujais S, Nolph K, Blake P, Burkart J, Coles G, Kawaguchi Y,
Kawanishi H, Korbet S, Krediet R, Lindholm B, Oreopoulus D,
Rippe B, Selgas R (2000) Evaluation and management of
ultrafiltration problems in peritoneal dialysis. Perit Dial Int 20
[Suppl 4]:S5–S21
65. Kiernan L, Kliger A, Gorban-Brennan N, Juergensen P, Tesin D,
Vonesh E, Finkelstein F (1995) Comparison of CAPD related
infections with different, Y-tubing“exchange systems. J Am Soc
Nephrol 5:1835–1838
66. Monteon F, Corra-Rotter P, Paniagua R, Amato D, Hurtado ME,
Medina JL, Salcedo RM, Garcia E, Matos M, Kaji J, Vazquez R,
Ramos A, Schettino MA, Moran J (1998) Prevention of peritonitis
Pediatr Nephrol (2009) 24:1453–1464 1463with disconnect systems in CAPD. The Mexican Nephrology
Collaborative Study Group. Kidney Int 54:2123–2128
67. Warady BA, Schaefer FS (2004) Peritonitis. In: Warady BA,
Schaefer FS, Fine RN, Alexander SR (eds) Pediatric dialysis.
Kluwer Academic Publishers, Dordrecht, pp 393–413
68. Dell’Aquila R, Rodighiero MP, Spano M, Di Loreto P, Ocampo
Kohn C, Cruz D, Polanco N, Kuang D, Corradi V, De Cal M,
Ronco C (2007) Advances in the technology of automated, tidal
and continuous flow peritoneal dialysis. Perit Dial Int 27 [Suppl
2]:S130–S137
69. Edefonti A, Boccola S, Picca M, Paglialonga F, Ardissino G,
Marra G, Ghio L, Parisotto MT (2003) Treatment data during
pediatric home peritoneal dialysis. Pediatr Nephrol 18:560–
564
70. Gallar P, Vigil A, Rodriguez I, Ortega O, Guterriez M, Hurtado J,
Oliet A, Ortiz M, Mon C, Herrero JC, Lentisco C (2007) Two-
year experience with telemedicine in the follow-up of patients in
home peritoneal dialysis. J Telemed Telecare 13:288–292
71. Nakamoto H (2007) Telemedicine system for patients on
continuous ambulatory peritoneal dialysis. Perit Dial Int 27
[Suppl 2]:S21–S26
72. Cargill A, Watson AR (2003) Telecare support for patients
undergoing chronic peritoneal dialysis. Perit Dial Int 23:91–94
73. Brunkhorst R, Fromm S, Wrenger E, Berke A, Petersen R, Riede
G, Westphale J, Zamore E, Ledebo I (1998) Automated peritoneal
dialysis with “online”-prepared bicarbonate-buffered dialysate:
Technique and first clinical experiences. Nephrol Dial Transplant
13:3189–3192
74. Ronco C, Amerling R (2006) Continuous flow peritoneal dialysis:
current state-of-the-art and obstacles to further development.
Contrib Nephrol 150:310–320
75. Woodrow G (2007) Methodology of assessment of fluid status and
ultrafiltration problems. Perit Dial Int 27 [Suppl 2]:S143–S147
76. Fischbach M, Terzic J, Menouer S, Soulami K, Dangelser C,
Helmstetter A, Gehant F (2001) Effects of automated peritoneal
dialysis on residual daily urinary volume in children. Adv Perit
Dial 17:269–273
77. Morgenstern BZ, Wuhl E, Nair KS, Warady BA, Schaefer F
(2006) Anthropometric prediction of total body water in children








1464 Pediatr Nephrol (2009) 24:1453–1464